Saccharomyces boulardii

Phase 3Small molecule

BBiocodex

Saccharomyces boulardii is one of 40 small molecule programs targeting Diarrhea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Irritable Bowel SyndromeRecruiting

Bismuth Quadruple TherapyRecruiting

Irritable Bowel SyndromePhase 3

Recruiting

Bismuth Quadruple TherapyPhase 3

Recruiting

Competition

Competitive Landscape

44 competitors in Irritable Bowel Syndrome

#DrugCompanyPhaseTrials

Linzess

AbbVie

Approved

12 2

Resotran

Takeda

Approved

2 3

Cymbalta

Jazz Pharmaceuticals

Approved

2 4

Lexapro

AbbVie

Approved

1 5

Nurtec

Azulfidine

Golytely

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 9

Alinia

RRomark Laboratories L.C.

Approved

2 10

VIOKACE

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Irritable Bowel Syndrome

NCT07168434

Clinical

Trials by Indication[1]

Irritable Bowel Syndrome3 trials

Saccharomyces Boulardii in Irritable Bowel Syndrome

Completed·—·Phase 3·NCT00589771·72 enrolled

Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome

Unknown status·—·Phase 4·NCT00543478·42 enrolled

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

Recruiting·BBiocodex·Phase 3·NCT07168434·406 enrolled

Helicobacter Pylori3 trials

Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

Completed·HHuazhong University of Science and Technology·N/A·NCT03688828·360 enrolled

Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori

Completed·TThe Third Xiangya Hospital of Central South University·N/A·NCT05191875·106 enrolled

Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii

Unknown status·CClinical Centre of Serbia·Phase 4·NCT03997279·200 enrolled

Heart Failure2 trials

GutHeart: Targeting Gut Microbiota to Treat Heart Failure

Unknown status·OOslo University Hospital·Phase 2·NCT02637167·150 enrolled

A Pilot Study of Probiotic Saccharomyces Boulardii Use in Chronic Heart Failure Patients. Estudo PROICA

Completed·UUniversidade Federal Fluminense·Phase 2·NCT01500343·20 enrolled

Liver Transplant1 trial

Effect of Saccharomyces Boulardii in Patients in the Waiting List for Liver Transplant

Completed·FFederal University of Minas Gerais·Phase 2·NCT01762748·18 enrolled

Immunodeficiency1 trial

Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial

Completed·BBiocodex·Phase 2·NCT00002088·100 enrolled

10 more indications

Unknown status·FFakultas Kedokteran Universitas Indonesia·N/A·NCT05451433·52 enrolled

Bismuth Quadruple Therapy1 trial

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

Recruiting·YYongquan Shi·Phase 4·NCT07139366·1,248 enrolled

Chronic Periodontitis1 trial

Effect Of A Locally Delivered Probiotic Sacchraomyces Boulardii In The Management Of Chronic Periodontitis

Completed·TTatyasaheb Kore Dental College·Phase 1/2·NCT03516370·31 enrolled

Growth1 trial

Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth

Completed·CCentro de Educación Medica e Investigaciones Clínicas Norberto Quirno·Phase 4·NCT04627337·71 enrolled

Prevention1 trial

Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea

Terminated·BBernhard Nocht Institute for Tropical Medicine·Phase 3·NCT01143272·477 enrolled

Helicobacter Pylori Infection1 trial

Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection

Not yet recruiting·ZZhongda Hospital·N/A·NCT07012785·208 enrolled

Diarrhea1 trial

Comparison of Effectiveness of Zinc Supplementation With ORS and Bacillus Clausii Versus Zinc With ORS and Saccharomyces Boulardii in Acute Watery Diarrhea in Paediatric Patients

Completed·RRESnTEC, Institute of Research·N/A·NCT06540209·60 enrolled

Recurrent Uti1 trial

A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections

Completed·AAnn & Robert H Lurie Children's Hospital of Chicago·Phase 1·NCT06149676·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Saccharomyces boulardii. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Saccharomyces boulardii compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Saccharomyces boulardii. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocodex company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBiocodex

Saccharomyces boulardii

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Irritable Bowel Syndrome3 trials

Helicobacter Pylori3 trials

Heart Failure2 trials

Liver Transplant1 trial

Immunodeficiency1 trial

Necrotizing Enterocolitis1 trial

Systemic Sclerosis1 trial

Quality of Life1 trial

Bismuth Quadruple Therapy1 trial

Chronic Periodontitis1 trial

Growth1 trial

Prevention1 trial

Helicobacter Pylori Infection1 trial

Diarrhea1 trial

Recurrent Uti1 trial

References

Drug Info

Quick Facts

Related News